{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:11:44Z","timestamp":1792059104081,"version":"4.4.0"},"reference-count":40,"publisher":"Japan Endocrine Society","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2017]]},"DOI":"10.1507\/endocrj.ej16-0449","type":"journal-article","created":{"date-parts":[[2016,12,2]],"date-time":"2016-12-02T22:02:33Z","timestamp":1480716153000},"page":"269-281","source":"Crossref","is-referenced-by-count":99,"title":["Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial"],"prefix":"10.1507","volume":"64","author":[{"given":"Ryotaro","family":"Bouchi","sequence":"first","affiliation":[{"name":"Department of Molecular Endocrinology and Metabolism, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujiro","family":"Nakano","sequence":"additional","affiliation":[{"name":"Department of Molecular Endocrinology and Metabolism, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Department of Molecular Endocrinology and Metabolism, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takato","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Department of Molecular Endocrinology and Metabolism, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Murakami","sequence":"additional","affiliation":[{"name":"Department of Molecular Endocrinology and Metabolism, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Minami","sequence":"additional","affiliation":[{"name":"Department of Molecular Endocrinology and Metabolism, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Izumiyama","sequence":"additional","affiliation":[{"name":"Department of Molecular Endocrinology and Metabolism, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan"},{"name":"Center for Medical Welfare and Liaison Services, Tokyo Medical and Dental University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koshi","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Molecular Endocrinology and Metabolism, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan"},{"name":"Department of Preemptive Medicine and Metabolism, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanobu","family":"Yoshimoto","sequence":"additional","affiliation":[{"name":"Department of Molecular Endocrinology and Metabolism, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Molecular Endocrinology and Metabolism, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Nauck M (2016) Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. <i>Diabetes Obes Metab<\/i> 18: 203-216.","DOI":"10.1111\/dom.12591"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Du Q, Wang YJ, Yang S, Zhao YY, Han P (2014) Liraglutide for the treatment of type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials. <i>Adv Ther<\/i> 31: 1182-1195.","DOI":"10.1007\/s12325-014-0164-2"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Robinson LE, Holt TA, Rees K, Randeva HS, O&rsquo;Hare JP (2013) Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. <i>BMJ Open<\/i> 3: e001986.","DOI":"10.1136\/bmjopen-2012-001986"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Jendle J, Nauck MA, Matthews DR, Frid A, Hermansen K, <i>et al<\/i>. (2009) Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. <i>Diabetes Obes Metab<\/i> 11: 1163-1172.","DOI":"10.1111\/j.1463-1326.2009.01158.x"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Inoue K, Maeda N, Kashine S, Fujishima Y, Kozawa J, <i>et al<\/i>. (2011) Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes. <i>Cardiovasc Diabetol<\/i> 10: 109.","DOI":"10.1186\/1475-2840-10-109"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, <i>et al<\/i>. (2005) Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. <i>Lancet<\/i> 366: 1640-1649.","DOI":"10.1016\/S0140-6736(05)67663-5"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Fujimoto WY, Bergstrom RW, Boyko EJ, Chen KW, Leonetti DL, <i>et al<\/i>. (1999) Visceral adiposity and incident coronary heart disease in Japanese-American men. The 10-year follow-up results of the Seattle Japanese-American Community Diabetes Study. <i>Diabetes Care<\/i> 22: 1808-1812.","DOI":"10.2337\/diacare.22.11.1808"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Britton KA, Massaro JM, Murabito JM, Kreger BE, Hoffmann U, <i>et al<\/i>. (2013) Body fat distribution, incident cardiovascular disease, cancer, and all-cause mortality. <i>J Am Coll Cardiol <\/i>62: 921-925.","DOI":"10.1016\/j.jacc.2013.06.027"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, <i>et al<\/i>. (2016) Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. <i>N Engl J Med<\/i> 375: 311-322.","DOI":"10.1056\/NEJMoa1603827"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Targher G, Bertolini L, Rodella S, Tessari R, Zenari L, <i>et al<\/i>. (2007) Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. <i>Diabetes Care<\/i> 30: 2119-2121.","DOI":"10.2337\/dc07-0349"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Kengne AP, Batty GD, Hamer M, Stamatakis E, Czernichow S (2012) Association of C-reactive protein with cardiovascular disease mortality according to diabetes status: pooled analyses of 25,979 participants from four U.K. prospective cohort studies. <i>Diabetes Care<\/i> 35: 396-403.","DOI":"10.2337\/dc11-1588"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Fox CS, Matsushita K, Woodward M, Bilo HJ, Chalmers J, <i>et al<\/i>. (2012) Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. <i>Lancet<\/i> 380: 1662-1673.","DOI":"10.1016\/S0140-6736(12)61350-6"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus, Seino Y, Nanjo K, Tajima N, Kadowaki T, <i>et al<\/i>. (2010) Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus. <i>J Diabetes Investig <\/i>1: 212-228.","DOI":"10.1111\/j.2040-1124.2010.00074.x"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, et al. (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53: 982-992.","DOI":"10.1053\/j.ajkd.2008.12.034"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Bouchi R, Nakano Y, Ohara N, Takeuchi T, Murakami M, <i>et al<\/i>. (2016) Clinical relevance of dual-energy X-ray absorptiometry (DXA) as a simultaneous evaluation of fatty liver disease and atherosclerosis in patients with type 2 diabetes. <i>Cardiovasc Diabetol<\/i>15: 64.","DOI":"10.1186\/s12933-016-0384-7"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Bouchi R, Takeuchi T, Akihisa M, Ohara N, Nakano Y, <i>et al<\/i>. (2016) Increased visceral adiposity with normal weight is associated with prevalence of non-alcoholic fatty liver disease in Japanese patients with type 2 diabetes. <i>J Diabetes Investig<\/i> 7: 607-614.","DOI":"10.1111\/jdi.12443"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Ishii H (2012) Development and psychometric validation of the Diabetes Therapy-Related QOL (DTR-QOL) questionnaire. <i>J Med Econ<\/i> 15: 556-563.","DOI":"10.3111\/13696998.2012.665111"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Vanderheiden A, Harrison LB, Warshauer JT, Adams-Huet B, Li X, <i>et al<\/i>.(2016) Mechanisms of Action of Liraglutide in Patients With Type 2 Diabetes Treated With High-Dose Insulin. <i>J Clin Endocrinol Metab<\/i> 101: 1798-1806.","DOI":"10.1210\/jc.2015-3906"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Vanderheiden A, Harrison L, Warshauer J, Li X, Adams-Huet B, <i>et al<\/i>. (2016) Effect of Adding Liraglutide vs Placebo to a High-Dose lnsulin Regimen in Patients With Type 2 Diabetes: A Randomized Clinical Trial. <i>JAMA Intern Med<\/i> 176: 939-947.","DOI":"10.1001\/jamainternmed.2016.1540"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Targher G, Bertolini L, Rodella S, Tessari R, Zenari L, <i>et al<\/i>. (2007) Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. <i>Diabetes Care<\/i> 30: 2119-2121.","DOI":"10.2337\/dc07-0349"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Hamaguchi E, Takamura T, Sakurai M, Mizukoshi E, Zen Y, <i>et al<\/i>. (2010) Histological course of nonalcoholic fatty liver disease in Japanese patients: tight glycemic control, rather than weight reduction, ameliorates liver fibrosis. <i>Diabetes Care<\/i> 33: 284-286.","DOI":"10.2337\/dc09-0148"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, <i>et al<\/i>. (2010) Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. <i>N Engl J Med <\/i>362: 1675-1685.","DOI":"10.1056\/NEJMoa0907929"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, <i>et al<\/i>. (2016) Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. <i>Lancet<\/i> 387: 679-690.","DOI":"10.1016\/S0140-6736(15)00803-X"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Smits MM, Tonneijck L, Muskiet MH, Kramer MH, Pouwels PJ, <i>et al<\/i>. (2016) Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial. <i>Diabetologia<\/i> 59: 2588-2593.","DOI":"10.1007\/s00125-016-4100-7"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Seino Y, Kaneko S, Fukuda S, Osonoi T, Shiraiwa T, <i>et al<\/i>. (2016) Combination therapy with liraglutide and insulin in Japanese patients with type 2 diabetes: A 36-week, randomized, double-blind, parallel-group trial. <i>J Diabetes Investig<\/i> 7: 565-573.","DOI":"10.1111\/jdi.12457"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Usui R, Yabe D, Kuwata H, Murotani K, Kurose T, <i>et al<\/i>. (2015) Retrospective analysis of safety and efficacy of liraglutide monotherapy and sulfonylurea-combination therapy in Japanese type 2 diabetes: Association of remaining &beta;-cell function and achievement of HbA1c target one year after initiation. <i>J Diabetes Complications<\/i> 29: 1203-1210.","DOI":"10.1016\/j.jdiacomp.2015.07.020"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Kodera R, Shikata K, Kataoka HU, Takatsuka T, Miyamoto S, <i>et al<\/i>.(2011) Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. <i>Diabetologia<\/i> 54: 965-978.","DOI":"10.1007\/s00125-010-2028-x"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Fujita H, Morii T, Fujishima H, Sato T, Shimizu T, <i>et al<\/i>. (2014) The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential. <i>Kidney Int <\/i>85: 579-589.","DOI":"10.1038\/ki.2013.427"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. von Scholten BJ, Hansen TW, Goetze JP, Persson F, Rossing P (2015) Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes. <i>J Diabetes Complications <\/i>29: 670-674.","DOI":"10.1016\/j.jdiacomp.2015.04.004"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Zavattaro M, Caputo M, Sam&agrave; MT, Mele C, Chasseur L, <i>et al<\/i>. (2015) One-year treatment with liraglutide improved renal function in patients with type 2 diabetes: a pilot prospective study. <i>Endocrine<\/i> 50: 620-626.","DOI":"10.1007\/s12020-014-0519-0"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Smits MM, Tonneijck L, Muskiet MH, Hoekstra T, Kramer MH, <i>et al<\/i>. (2015) Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes. <i>BMJ Open<\/i> 5: e009579.","DOI":"10.1136\/bmjopen-2015-009579"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Hanai K, Babazono T, Nyumura I, Toya K, Ohta M, <i>et al<\/i>. (2010) Involvement of visceral fat in the pathogenesis of albuminuria in patients with type 2 diabetes with early stage of nephropathy. <i>Clin Exp Nephrol<\/i> 14: 132-136.","DOI":"10.1007\/s10157-009-0245-8"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Abel ED, O&rsquo;Shea KM, Ramasamy R (2012) Insulin resistance: metabolic mechanisms and consequences in the heart. <i>Arterioscler Thromb Vasc Biol<\/i> 32: 2068-2076.","DOI":"10.1161\/ATVBAHA.111.241984"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB (1999) Elevated C-reactive protein levels in overweight and obese adults. <i>JAMA<\/i> 282: 2131-2135.","DOI":"10.1001\/jama.282.22.2131"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Fr&ouml;hlich M, Imhof A, Berg G, Hutchinson WL, Pepys MB, <i>et al<\/i>.(2000) Association between C-reactive protein and features of the metabolic syndrome: a population-based study. <i>Diabetes Care<\/i> 23: 1835-1839.","DOI":"10.2337\/diacare.23.12.1835"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Barinas-Mitchell E, Cushman M, Meilahn EN, Tracy RP, Kuller LH (2001) Serum levels of C-reactive protein are associated with obesity, weight gain, and hormone replacement therapy in healthy postmenopausal women. <i>Am J Epidemiol<\/i> 153: 1094-1101.","DOI":"10.1093\/aje\/153.11.1094"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Best LG, Zhang Y, Lee ET, Yeh JL, Cowan L, <i>et al<\/i>. (2005) C-reactive protein as a predictor of cardiovascular risk in a population with a high prevalence of diabetes: the Strong Heart Study. <i>Circulation <\/i>112: 1289-1295.","DOI":"10.1161\/CIRCULATIONAHA.104.489260"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Mora S, Rifai N, Buring JE, Ridker PM (2006) Circulation. Additive value of immunoassay-measured fibrinogen and high-sensitivity C-reactive protein levels for predicting incident cardiovascular events. <i>Circulation<\/i> 114: 381-387.","DOI":"10.1161\/CIRCULATIONAHA.106.634089"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Park SW, Goodpaster BH, Lee JS, Kuller LH, Boudreau R, <i>et al<\/i>. (2009) Excessive loss of skeletal muscle mass in older adults with type 2 diabetes. <i>Diabetes Care<\/i> 32: 1993-1997.","DOI":"10.2337\/dc09-0264"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Mavros Y, Kay S, Anderberg KA, Baker MK, Wang Y, <i>et al<\/i>. (2013) Changes in insulin resistance and HbA1c are related to exercise-mediated changes in body composition in older adults with type 2 diabetes: interim outcomes from the GREAT2DO trial. <i>Diabetes Care <\/i>36: 2372-2379.","DOI":"10.2337\/dc12-2196"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/64\/3\/64_EJ16-0449\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T06:22:23Z","timestamp":1568614943000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/64\/3\/64_EJ16-0449\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej16-0449","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}